Xeriant (XERI) 10-Q 14 Nov 24 2025 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2024	Nov. 11, 2024
Cover [Abstract]
Entity Registrant Name	XERIANT, INC.
Entity Central Index Key	0001481504
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Entity Common Stock Shares Outstanding		588,884,486
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54277
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-1519178
Entity Address Address Line 1	Innovation Centre 1
Entity Address Address Line 2	3998 FAU Boulevard
Entity Address Address Line 3	Suite 309
Entity Address City Or Town	Boca Raton
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33431
City Area Code	561
Local Phone Number	491-9595
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Current assets
Cash	$ 300,022	$ 653,117
Prepaids	11,792	2,931
Note receivable	8,163	8,163
Total current assets	319,977	664,211
Deposits	12,546	12,546
Property & equipment, net	3,617	3,995
Operating lease right-of-use asset, net	18,687	32,253
Total assets	354,827	713,005
Current liabilities
Accounts payable and accrued liabilities	1,014,315	1,211,533
Accrued liabilities, related party	17,500	20,000
Shares to be issued	75,200	75,200
Convertible notes payable, net of discount - in default	5,850,000	5,850,000
Convertible notes payable, net of discount	1,874,331	2,132,529
Lease liability, current	21,144	36,197
Total liabilities	8,852,490	9,325,459
Stockholders' deficit
Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 570,184,486 and 524,853,304 shares issued and outstanding at September 30, 2024 and June 30, 2024, respectively	5,702	5,248
Common stock to be issued	51,950	51,950
Additional paid in capital	21,385,746	20,899,187
Accumulated deficit	(27,073,761)	(26,708,915)
Total stockholders' deficit	(5,630,346)	(5,752,513)
Non-controlling interest	(2,867,317)	(2,859,941)
Total stockholders' deficit	(8,497,663)	(8,612,454)
Total liabilities and stockholders' deficit	354,827	713,005
Series B Preferred Shares [Member]
Stockholders' deficit
Preferred Stock Value	10	10
Series A Preferred Shares [Member]
Stockholders' deficit
Preferred Stock Value	$ 7	$ 7

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Jun. 30, 2024
Common stock, shares par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	570,184,486	524,853,304
Common stock, shares outstanding	570,184,486	524,853,304
Series B Preferred Shares [Member]
Preferred stock, shares par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares designated	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Series A Preferred Shares [Member]
Preferred stock, shares par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares designated	3,500,000	3,500,000
Preferred stock, shares issued	699,416	705,895
Preferred stock, shares outstanding	699,416	705,895

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Consulting and advisory fees	$ 88,983	$ 51,695
Related party consulting fees	123,000	97,500
General and administrative expenses	56,445	52,399
Professional fees	63,806	90,314
Research and development expense	26,561	26,982
Total operating expenses	358,795	318,890
Loss from operations	(358,795)	(318,890)
Other expenses:
Amortization of debt discount	(16,802)	0
Interest expense	(61,617)	(20,674)
Gain on extinguishment of debt	64,992	0
Change in fair value of convertible bridge loans	0	(2,448)
Total other expense	(13,427)	(23,122)
Net loss before income tax expense	(372,222)	(342,012)
Income tax expense	0	0
Net loss	(372,222)	(342,012)
Less net loss attributable to noncontrolling interest	(7,376)	(7,922)
Net loss attributable to common stockholders	$ (364,846)	$ (334,090)
Net loss per common share - basic and diluted	$ 0	$ 0
Weighted average number of common shares outstanding - basic and diluted	547,575,614	393,756,221

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS DEFICIT (UNAUDITED) - USD ($)	Total	Common Stock	Common Stock To Be Issued	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest	Series A Preferred Stocks [Member]	Series B, Preferred Stock
Balance, shares at Jun. 30, 2023		389,433,144					757,395	1,000,000
Balance, amount at Jun. 30, 2023	$ (6,620,100)	$ 3,894	$ 51,950	$ 19,789,793	$ (23,638,461)	$ (2,827,294)	$ 8	$ 10
Conversion of Series A Preferred to Common Stock, shares		5,000,000					(5,000)
Conversion of Series A Preferred to Common Stock, amount	0	$ 50	0	(50)	0	0	$ 0	0
Conversion of convertible notes payable and accrued interest into common stock, shares		6,600,000
Conversion of convertible notes payable and accrued interest into common stock, amount	66,000	$ 66	0	65,934	0	0	0	0
Net loss	(342,012)	$ 0	0	0	(334,090)	(7,922)	$ 0	$ 0
Balance, shares at Sep. 30, 2023		401,033,144					752,395	1,000,000
Balance, amount at Sep. 30, 2023	(6,896,112)	$ 4,010	51,950	19,855,677	(23,972,551)	(2,835,216)	$ 8	$ 10
Balance, shares at Jun. 30, 2024		524,853,304					705,895	1,000,000
Balance, amount at Jun. 30, 2024	(8,612,454)	$ 5,248	51,950	20,899,187	(26,708,915)	(2,859,941)	$ 7	$ 10
Conversion of Series A Preferred to Common Stock, shares		6,479,000					(6,479)
Conversion of Series A Preferred to Common Stock, amount	0	$ 65	0	(65)	0	0	$ 0	0
Conversion of convertible notes payable and accrued interest into common stock, shares		26,950,000
Conversion of convertible notes payable and accrued interest into common stock, amount	269,501	$ 270	0	269,231	0	0	0	0
Net loss	(372,222)	$ 0	0	0	(364,846)	(7,376)	0	0
Stock issued for services, shares		11,902,182
Stock issued for services, amount	217,512	$ 119	0	217,393	0	0	$ 0	$ 0
Balance, shares at Sep. 30, 2024		570,184,486					699,416	1,000,000
Balance, amount at Sep. 30, 2024	$ (8,497,663)	$ 5,702	$ 51,950	$ 21,385,746	$ (27,073,761)	$ (2,867,317)	$ 7	$ 10

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities
Net loss	$ (372,222)	$ (342,012)
Adjustments to reconcile net loss to net
Depreciation and amortization	378	378
Stock issued for services	217,512	0
Change in fair value of convertible bridge loans	0	2,448
Amortization of debt discount	16,802	0
Amortization of right of use asset	13,566	12,146
Changes in operating assets and liabilities:
Prepaids	(8,861)	815
Accounts payable and accrued liabilities	(197,218)	41,274
Accrued liabilities, related party	(7,999)	(10,000)
Lease liabilities	(15,053)	(13,176)
Net cash from operating activities	(353,095)	(308,127)
Cash Flows from Investing Activities
Cash repayments for notes receivable	0	(139,947)
Net cash from financing activities	0	(139,947)
Cash Flows from Financing Activities
Proceeds from convertible bridge loans	0	411,000
Net cash from financing activities	0	411,000
Net change in cash	(353,095)	(37,074)
Cash at beginning of period	653,117	61,625
Cash at end of period	300,022	24,551
Supplemental Cash Flow Information
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Conversion of convertible notes payable and accrued interest	$ 269,501	$ 66,000

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	3 Months Ended
	Sep. 30, 2024
ORGANIZATION AND NATURE OF BUSINESS
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS Company Overview Xeriant, Inc. (the “Company”) is dedicated to the discovery, development and commercialization of advanced materials and technology related to next generation air and spacecraft, which can be successfully integrated and commercialized for deployment across multiple industrial sectors. The Company seeks to partner with and acquire strategic interests in visionary companies that accelerate this mission. Xeriant’s advanced materials line will be marketed under the DUREVER™ brand, and includes NEXBOARD™, an eco-friendly, patent-pending composite building panel made from plastic and cellulose waste and a proprietary flame retardant, primarily designed to be a replacement for traditional building materials such as drywall, plywood, OSB, MDF, MgO board and other materials used in construction. Operating History The Company is a development-stage enterprise with a limited operating history with no sales, and operating losses since its inception. The Company had two joint ventures, one in the area of aerospace that was effective May 31, 2021, and terminated on May 31, 2023, the other involving advanced materials that was effective April 2, 2022, and terminated June 30, 2023. Advanced Materials A primary focus of the Company is the development and commercialization of eco-friendly advanced materials which have applications across a broad range of industries and the potential to generate significant near-term revenue. The Company’s strategy encompasses licensing arrangements, joint ventures, or combinations which could allow for more rapid access to the market with reduced capital requirements and financial risk. Some partner companies may provide production and distribution infrastructure, which could streamline testing and certification as well as add brand recognition. Once the Company establishes sufficient production capabilities, the advanced materials may be sold as standalone products, enhancements to existing products, or used in the development of proprietary products under new trademarked brands owned by the Company. The Company is exploring manufacturing and branding opportunities for specific products derived from advanced materials acquired or developed, which would involve setting up production facilities, equipment, systems and supply chains. Throughout the second half of 2023, Xeriant began developing its own advanced materials, including proprietary flame-retardant technology for polymers contained in recycled materials. The Company also began testing a number of production processes to manufacture its eco-friendly, patent pending, composite construction panel called NEXBOARD ™ On August 12, 2022, the Company filed a trademark application with the U.S. Patent and Trademark Office for “NEXBOARD,” with respect to construction panels, namely, composite sheets and panels composed primarily of plastic, reinforcement materials and fire-retardant chemicals for use in walls, ceilings, flooring, framing, siding, roofing and decking. The trademark filing was intentionally broad and based upon demand for a general all-purpose construction panel made from a mixture of fire-retardant and recycled materials. Xeriant has also filed a trademark application for “DUREVER™.” On March 31, 2023, the Company filed a provisional patent application titled “Multilayered Fire-Resistant Polymer Composite and Method for Producing Same,” for a method of producing a unique fire-resistant thermoplastic and fiber composite material which may be formed or shaped into various construction products of different thicknesses and dimensions. This green material will be composed primarily of recycled plastic, cellulose and ecofriendly fire-retardant chemicals, including but not limited to use in walls, ceilings, flooring, framing, siding, roofing, molding, and decking, used in construction. On April 1, 2024, the Company filed a non-provisional U.S. patent application claiming priority to the filing date of the 2023 related provisional patent application described herein. Subject to available capital, the Company is planning to build manufacturing facilities in the United States for the production of NEXBOARD™ in order to meet market demand, or alternatively license the technology and process. The Company has identified companies for near-term contract manufacturing, has potential locations identified for a pilot plant and larger manufacturing facilities, received bids for specialized manufacturing equipment, developed timetables related to the action plan, and selected a managing director with decades of experience who would like to oversee the startup of production, expansion and operations. Aerospace The Company seeks to develop or acquire and commercialize disruptive, high-growth-potential technologies in aerospace, including next-generation air and spacecraft, that have potential applications in other industries. The areas of focus that are reshaping the future of aerospace include advanced materials, advanced air mobility, unmanned aerial systems, AI, hypersonics, communications, cybersecurity, satellites, and renewable energy technology. The Company’s initial concentration was on the emerging aviation market called advanced air mobility (AAM), the transition to more efficient, eco-friendly, automated and convenient flight operations, enabled by the convergence of technological advancements in design and engineering, composite materials, propulsion systems, battery energy density and manufacturing processes. Next-generation aircraft being developed for this market offer low-cost, on-demand flight for passengers and cargo, utilizing lower altitude airspace and bypassing the traditional hub-and-spoke airport network with vertical takeoff and landing (VTOL) capabilities. Many of these lightweight aircraft are electrically powered through either hybrid or pure battery systems, which allows for quieter, low emission flights over urban areas, however with limited speed and range. Hydrogen powered aircraft have already been prototyped and are expected to become more prevalent over the next decade. The development of solid-state hydrogen technology may address the safety, large-area storage requirement limitations for gaseous-state hydrogen. The Company plans to partner with and acquire strategic interests in visionary companies that accelerate our mission of commercializing critical breakthrough aerospace technologies which enhance sustainability, performance, and safety. Effective May 31, 2021, the Company entered into a 50/50 Joint Venture Agreement with XTI Aircraft Company (“XTI”), for the purpose of completing the preliminary design review (“PDR”) of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric vertical takeoff and landing (VTOL) fixed-wing aircraft. The aircraft’s unique design elements along with the $1 billion in pre-orders and reservations, enticed Xeriant to invest $5.5 million to complete the PDR, which was accomplished in the first quarter of 2022 according to XTI. The TriFan 600 was purported to become the fastest, longest-range VTOL aircraft in the world and the first commercial fixed-wing VTOL airplane. According to recent public disclosures by XTI, pre-orders and reservations of the TriFan 600 total approximately $7 billion. On May 17, 2022, Xeriant signed a Letter Agreement with XTI related to the introduction of XTI to Inpixon, a Nasdaq-listed company. Under this Letter Agreement, if there was a combination or other transaction between XTI and Inpixon, Xeriant would receive compensation of 6 percent of XTI fully diluted pre-merger shares, and XTI would assume the obligations of Xeriant’s Senior Secured Note with Auctus Fund, LLC. On July 25, 2023, Inpixon filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding, which was a compensation triggering event. Inpixon subsequently filed an S-4/A registration statement on October 6, 2023. On December 6, 2023, the Company initiated legal proceedings against XTI. See Litigation In the area of aerospace, management believes that Xeriant can grow expeditiously by acquiring technology and assets primarily through acquisitions, joint ventures, strategic investments, and licensing arrangements. As a publicly traded company, the Company offers partner companies such benefits as improved access to capital, higher valuations and lower risk through the shared ownership of a diversified portfolio, while allowing these entities to maintain independence in their distinct operations to focus on their fields of expertise. Cost savings and efficiencies may be realized from sharing non-operational functions such as finance, legal, tax, sales & marketing, human resources, purchasing power, as well as investor and public relations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC and BlueGreen Composites, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) for interim information and in accordance with the instructions to Form 10Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. All significant intercompany balances and transactions have been eliminated. The unaudited condensed consolidated financial statements, which include the accounts of the Company and its subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with U.S. GAAP and presented in US dollars. The fiscal year end is June 30. Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred net losses since inception and has an accumulated deficit of $27,073,761 as of September 30, 2024. During the three months ended September 30, 2024, the Company’s net loss was $372,222 and at September 30, 2024, the Company had a working capital deficit of $8,532,513. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on its historical rate of expenditures, the Company expects to expend its available cash in approximately two months from November 14, 2024. Management’s plans include raising capital through the issuance of common stock and debt to fund operations and, eventually, the generation of revenue through its business. The Company does not expect to generate any significant revenue in the foreseeable future. The Company is in immediate need of further working capital and is seeking options, with respect to financing, in the form of debt, equity or a combination thereof. Failure to raise adequate capital and generate adequate revenues could result in the Company having to curtail or cease operations. The Company’s ability to raise additional capital through the future issuances of the common stock is unknown. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable it to develop to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern; however, the accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC and BlueGreen Composites, LLC. The Company owns a 64% controlling interest in AAT; and a 100% interest in BlueGreen Composites, LLC. All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of warrants associated with convertible debt. Actual results could differ from these estimates. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. ASC subtopic 825-10, Financial Instruments The Company follows ASC subtopic 820-10, Fair Value Measurements and Disclosures Cash and Cash Equivalents For the purposes of the unaudited condensed consolidated statements of cash flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents. Impairment of Long-Lived Assets In accordance with ASC 360-10, Impairment and Disposal of Long-Lived Asset Convertible Debentures The Company adheres to the guidance in Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity on July 1, 2022 Stock-based Compensation The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. During the three months ended September 30, 2024 and 2023, the Company recognized $217,512 and $0, respectively. Leases The Company accounts for leases under ASU 2016-02. At the inception of a contract the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease right of use (“ROU”) assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is presented in operating expenses on the unaudited condensed consolidated statements of operations as rent expense. Finance leases are recorded as a finance lease liability and property and equipment asset, based on the present value of lease payments. The asset is depreciated, and the liability is amortized with interest expense incurred over the life of the lease. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the guidance to short term leases (leases with a lease term of twelve months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term. Investments The Company follows ASC 325-20, Cost Method Investments Research and Development Expenses Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $26,561 and $26,982 for the three months ended September 30, 2024 and 2023, respectively. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $2,035 and $6,356 for the three months ended September 30, 2024 and 2023, respectively, as general and administrative expenses. Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s consolidated federal tax return and any state tax returns are not currently under examination. The Company follows ASC subtopic 740-10, Income Taxes Basic Income (Loss) Per Share Under the provisions of ASC 260, “ Earnings per Share Three months ended September 30, 2024 2023 Warrants 118,968,828 104,802,161 Stock options 21,250,000 21,250,000 Convertible notes payable 861,438,676 103,383,909 Preferred stock 699,416,000 752,395,000 Total 1,701,073,504 981,831,070 Recent Accounting Pronouncements All other recent accounting pronouncements issued by the Financial Accounting Standards Board, did not or are not believed by management to have a material impact on the Company’s present or future unaudited condensed consolidated financial statements.

JOINT VENTURE

JOINT VENTURE	3 Months Ended
	Sep. 30, 2024
JOINT VENTURE
JOINT VENTURE	NOTE 3 – JOINT VENTURE Joint Venture with XTI Aircraft Effective May 31, 2021, Xeriant entered into a Joint Venture Agreement (the “Agreement”) with XTI Aircraft Company (“XTI”), a Delaware corporation, to form a joint venture with XTI (the “XTI JV”), named Eco-Aero, LLC, with the purpose of completing the preliminary design review (“PDR”) of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, eVTOL fixed wing aircraft. Under the Agreement, Xeriant contributed capital, technology, and strategic business relationships, and XTI contributed intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the XTI JV, and it is managed by a management committee consisting of five members, three appointed by Xeriant and two by XTI. The Company invested approximately $5.5 million into the joint venture after borrowing the funds from Auctus Fund LLC (“Auctus”) through a Senior Secured Promissory Note, through an introduction from Maxim Group, LLC, the Company’s investment banker at the time. The borrowed funds from Auctus were intended to be a bridge loan that would be resolved through an IPO (Initial Public Offering) and uplist to Nasdaq in a merger with XTI, which did not occur because XTI refused to move forward with the merger. The PDR was completed during the first quarter of 2022 according to XTI, which was the purpose of the joint venture. On May 17, 2022, Xeriant signed a Letter Agreement with XTI related to the introduction of XTI to Inpixon, a Nasdaq-listed company. Under this Letter Agreement, if there was a combination or other transaction between XTI and Inpixon, Xeriant would receive compensation of 6 percent of XTI fully diluted pre-merger shares, and XTI would assume the obligations of Xeriant’s Senior Secured Note with Auctus Fund, LLC. On May 31, 2023, the joint venture was terminated according to an Acceleration Event, which was 24 months from the start of the joint venture. On June 5, 2023, after suspecting that the obligations under the Letter Agreement were possibly being evaded, the Company transmitted a formal demand letter to XTI requesting compliance with the provisions outlined in the Letter Agreement, and in accordance with section 8 of the JV Agreement with XTI. On July 25, 2023, Inpixon filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding, which was a compensation triggering event. Inpixon subsequently filed an S-4/A registration statement on October 6, 2023. On December 6, 2023, the Company initiated legal proceedings against XTI. The Company analyzed the transaction under ASC 810, Consolidation The Company includes the assets and liabilities related to the VIE in the unaudited condensed consolidated balance sheets. Xeriant, Inc. provides cash to the VIE to fund its operations. The carrying amounts of the consolidated VIE’s assets and liabilities associated with the VIE subsidiary were as follows: September 30, 2024 June 30, 2024 Assets Cash $ - $ - Total Assets $ - $ - Liabilities Due from Xeriant Inc. $ 4,475,155 $ 4,475,155 Total Liabilities $ 4,475,155 $ 4,475,155

CONCENTRATION OF CREDIT RISKS

CONCENTRATION OF CREDIT RISKS	3 Months Ended
	Sep. 30, 2024
CONCENTRATION OF CREDIT RISKS
CONCENTRATION OF CREDIT RISKS	NOTE 4 – CONCENTRATION OF CREDIT RISKS The Company maintains accounts with financial institutions. All cash in checking accounts is non-interest bearing and is fully insured by the Federal Deposit Insurance Corporation (FDIC). At times, cash balances may exceed the maximum coverage provided by the FDIC on insured depositor accounts. The Company believes it mitigates its risk by depositing its cash and cash equivalents with major financial institutions. On September 30, 2024, and June 30, 2024, the Company had $0 in excess of FDIC insurance.

OPERATING LEASE RIGHT OF USE AS

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY	3 Months Ended
	Sep. 30, 2024
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY	NOTE 5 – OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company entered into a lease agreement commencing on November 1, 2019, through January 1, 2025, in which the first three months of rent were abated. Subsequent to the COVID-19 pandemic, the Company decided to continue to have all employees work from home and intends to build out the office space by the end of December 2023 to allow employees to work from the office beginning in January of 2024. The following table illustrates the base rent amounts over the term of the lease: Base Rent Periods November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063 Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is the Company’s incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of the Company’s leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in general and administrative expenses on the condensed consolidated statements of operations. During the three months ended September 30, 2024 and 2023, the Company recorded $13,257 and $13,285 in rent expense, respectively in general and administrative expenses on the unaudited condensed consolidated statements of operations. Right-of-use asset is summarized below: September 30, 2024 June 30, 2024 Office lease $ 220,448 $ 220,448 Less accumulated amortization (201,761 ) (188,195 ) Right of use assets, net $ 18,687 $ 32,253 Operating lease liability is summarized below: September 30, 2024 June 30, 2024 Office lease $ 21,144 $ 36,197 Less: current portion (21,144 ) (36,197 ) Long term portion $ - $ - Maturity of lease liabilities are as follows: Year ended June 30, 2025 21,410 Total future minimum lease payments 21,410 Less: Present value discount (266 ) Lease liability $ 21,144

CONVERTIBLE NOTES PAYABLE, IN D

CONVERTIBLE NOTES PAYABLE, IN DEFAULT	3 Months Ended
	Sep. 30, 2024
CONVERTIBLE NOTES PAYABLE, IN DEFAULT
CONVERTIBLE NOTES PAYABLE, IN DEFAULT	NOTE 6 – CONVERTIBLE NOTES PAYABLE, IN DEFAULT The carrying value of convertible notes payable as of September 30, 2023, and June 30, 2023, was $5,850,000. September 30, June 30, Convertible Notes Payable 2023 2023 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 5,850,000 Total face value $ 5,850,000 $ 5,850,000 Auctus Fund LLC Senior Secured Note Through Maxim Group, LLC, Xeriant was introduced to Auctus Fund LLC (“Auctus”) for the purpose of providing bridge loan funding to satisfy the requirements of a pending merger with XTI Aircraft under a letter of intent signed in September 2021. On October 27, 2021, the Company was issued a convertible note payable with Auctus with the principal of $6,050,000, consisting of $5,142,500, which was the actual amount funded, plus an original issue discount in the amount of $907,500 for interest on the unpaid principal amount at the rate of zero percent per annum from the issue date until the note becomes due and payable. The closing costs were $433,550, which included $308,550 in fees paid to Maxim and professional fees for completing the transaction. The Note had an initial due date of October 27, 2022. The Auctus Note provides the holder has the option to convert the principal balance to common stock of the Company at a conversion price of the lesser of (i) $0.1187 or (ii) 75% of the offering price per share divided by the number of shares of common stock. The Auctus Note is secured by the grant of a first priority security interest in the assets of the Company. In connection with the Auctus Note, the Company issued warrants indexed to an aggregate of 50,968,828 shares of common stock. The warrants have a term of five years and an exercise price of $0.1187. The exercise price can be adjusted downward to match the price of the Company’s most recent issuance of common shares. Effective August 1, 2022, the Company entered into an Amendment to the Senior Secured Promissory Note (the “First Amendment”) with Auctus pursuant to which the parties agreed to amend the Auctus Note. The Amendment (i) extended the maturity date of the Auctus Note to November 1, 2022, and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company’s common stock to a national securities exchange to November 1, 2022. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of common stock dated July 26, 2022 (the “Warrant”) at an exercise price of $0.09 per share and 5-year term; (ii) make a prepayment of the Note in the amount of $100,000; and (iii) cause a director of the Company to cancel his 10b-5(1) Plan. Effective December 27, 2022, the Company entered into a Second Amendment to the Senior Secured Promissory Note (the “Second Amendment”) with Auctus pursuant to which the parties agreed to further amend the Auctus Note. The Second Amendment (i) extended the maturity date of the Note, the obligation to uplist to a national securities exchange and acquisition of XTI Aircraft Company to March 15, 2023, and (ii) extended the date to file an S-1 registration statement to uplist the Company’s common stock to a national securities exchange to January 15, 2023. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 250,000,000 shares of Common Stock dated December 27, 2022 (the “New Warrant”) at an exercise price of $0.09 per share and 5-year term, and (ii) make two pre-payment installments of $50,000 on January 15, 2023, and February 15, 2023. On October 6, 2023, the Company received a conversion notice to issue 20,011,500 shares of the Company’s common stock to Auctus which shares were subsequently issued by the Company’s stock transfer agent and the value of the relating shares applied to interest on the Note. The Company is contesting the legality of this conversion and issuance which is a subject of the Company’s legal proceedings against Auctus. The Company tested the first modification (“First Amendment”) under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $3,570,366 for the year ended June 30, 2023. The Company tested the second modification (“Second Amendment”) under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $689,621 for the year ended June 30, 2023. On October 19, 2023, Xeriant filed a complaint against Auctus. See Litigation As of September 30, 2024, and June 30, 2024, a total of $50,000 remains outstanding, and is recorded within accounts payable and accrued liabilities on the unaudited condensed consolidated balance sheets. During the year ended June 30, 2024, the Company recorded $1,070,729 in default interest related to the note. On October 6, 2023, Auctus converted $200,115 in interest into 20,011,500 shares of common stock and on April 5, 2024, Auctus converted $227,067 in interest into 22,706,700 shares of common stock. As of September 30, 2024, and June 30, 2024, the balance of accrued interest of this note was $643,546.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Sep. 30, 2024
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE	NOTE 7 – CONVERTIBLE NOTES PAYABLE The carrying value of convertible notes payable, net of discount at September 30, 2024 and June 30, 2024 was as follows: September 30, June 30, Convertible Notes Payable 2024 2024 Convertible notes payable (10% interest) $ 1,905,000 $ 2,180,000 Less unamortized discount (30,669 ) (47,471 ) Total face value $ 1,874,331 $ 2,132,529 Between July 17, 2023 and June 26, 2024, the Company issued convertible bridge loans with an aggregate face value of $2,030,000. The notes have a coupon rate of 10% and a maturity date of one year. The Notes are convertible at a fixed price of $0.01 per share. In connection with the Notes, holders of $150,000 in principal were issued 15,000,000 warrants during the fiscal year ended June 30, 2024. These warrants have an exercise price of $0.01 per share and have a three-year expiration date. During the three months ended September 30, 2024 and 2023, the Company recorded $61,617 and $20,674 in interest expense related to these notes, respectively. During the year ended June 30, 2024, the Company marked up convertible bridge loans from their aggregate fair value of $249,702 to their face value of $270,000 and reclassified within the consolidated balance sheets under convertible notes payable. During the three months ended September 30, 2024, $245,000 in principal and $24,501 in accrued interest was converted into 26,950,000 shares of common stock. The Company evaluated the detachable warrants under the requirements of ASC 480 and concluded that the warrants do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “ Derivatives and Hedging Significant inputs and results arising from the BSM process are as follows for the redemption feature component of the warrants: Quoted market price on valuation date $0.016 - $0.022 Effective contractual conversion rates $0.01 Contractual term to maturity 3 years Market volatility: Volatility 137.43% - 137.86% Risk-adjusted interest rate 4.33% - 4.39%

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2024
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS Consulting fees During the three months ended September 30, 2024 and 2023, the Company recorded $55,000 and $57,500 respectively, in consulting fees to Ancient Investments, LLC, a Company owned by the Company’s CEO, Keith Duffy and the Company’s Executive Director of Corporate Operations, Scott Duffy. As of September 30, 2024 and June 30, 2024, $2,500 and $5,000 was accrued, respectively. For the three months ended September 30, 2024 and 2023, the Company recorded $30,000 and $21,000 respectively, in consulting fees to Edward DeFeudis, a Director of the Company. As of September 30, 2024 and June 30, 2024, $10,000 was accrued. During the three months ended September 30, 2024 and 2023, the Company recorded $23,000 and $14,000 respectively in consulting fees to AMP Web Services, a Company owned by the Company’s CTO, Pablo Lavigna. As of September 30, 2024 and June 30, 2024, $0 was accrued. During the three months ended September 30, 2024 and 2023, the Company recorded $15,000 and $5,000 respectively, in consulting fees to Keystone Business Development Partners, a Company owned by the Company’s CFO, Brian Carey. As of September 30, 2024 and June 30, 2024, $5,000 was accrued. The above amounts are not necessarily what third parties would agree to.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2024
Commitments and contingencies (Note 9)
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies Board of Advisors Agreements The Company has entered into Advisor Agreements with various advisory board members. The agreements provide for the following: On July 1, 2021, the Company agreed to issue to an advisor 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, and for each of the following three years (beginning July 1, 2022), an option to purchase an additional 1,000,000 common shares per year thereafter at a 25% discount to the average market price for the preceding 10 trading days. The agreement also provides for a 1% finder’s fee. On July 6, 2021, the Company provided an option to an advisor to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 250,000 common shares issued upon a strategic partnership with a major airline, $2,500 per formal meeting paid in common shares, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On July 28, 2021, the Company agreed to issue to an advisor 250,000 common shares immediately, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 5,000,000 common shares for bringing in a strategic partner that significantly strengthens the Company’s market position, $2,500 per formal meeting paid in cash, common shares or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. The agreement also provides for a 30% commission. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On August 9, 2021, the Company agreed to issue to an advisor 50,000 common shares vesting over the first year, $2,500 per meeting paid in cash, common shares, or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On August 20, 2021, the Company agreed to issue to an advisor 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 4,000,000 common shares at $0.12 per share, vesting quarterly over 24 months. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On March 1, 2022, the Company agreed to issue to an advisor 150,000 common shares vesting monthly over one year, $2,500 per meeting paid in cash, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On January 20, 2022, the Company agreed to issue to an advisor 150,000 common shares vesting monthly over one year, and $2,500 per meeting paid in cash and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. On March 20, 2022, the Company agreed to issue to an advisor 150,000 common shares vesting monthly over one year, and $2,500 per meeting paid in cash and an additional bonus of $25,000 paid in common shares issued at the end of each year of service. Advisory agreement is open ended and can be terminated by consent of both parties upon written notice. There were no Advisory Agreements executed during the three months ended September 30, 2024 or the year ended June 30, 2024.

EQUITY

EQUITY	3 Months Ended
	Sep. 30, 2024
EQUITY
EQUITY	NOTE 10 – EQUITY Common Stock As of September 30, 2024, and June 30, 2024, the Company had 5,000,000,000 shares of common stock authorized with a par value of $0.00001. There were 570,184,486 and 524,853,304 shares issued and outstanding as of September 30, 2024, and June 30, 2024, respectively. During the three months ended September 30, 2024, $245,000 in principal and $269,501 in accrued interest was converted into 26,950,000 shares of common stock. Series A Preferred Stock There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A preferred stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights: · Voting · Dividends · Conversion · The shares of Series A Preferred Stock are redeemable at the option of the Corporation at any time after September 30, 2022, upon not less than 30 days written notice to the holders. It is not mandatorily redeemable. As of September 30, 2024, and June 30, 2024, the Company had 699,416 and 705,895 shares of Series A preferred stock issued and outstanding, respectively. Series B Preferred Stock On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, grants 5,000 votes and no liquidation preference. Stock Options In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded no compensation expense for these options for the three months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was no unrecognized compensation cost related to non-vested portion of options granted. As of September 30, 2024, there are 21,250,000 options outstanding, of which 21,250,000 are exercisable. The weighted average remaining term is 0.30 years. A summary of the Company’s stock options activity is as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2024 21,250,000 $ 0.12 1.11 Granted - Exercised - - Canceled - - Outstanding at September 30, 2024 21,250,000 $ 0.12 0.76 $ - Exercisable at September 30, 2024 21,250,000 $ 0.12 0.30 $ - Significant inputs and results arising from the Black-Scholes process are as follows for the options: Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 181.21% - 275.73% Range of interest rates 0.20% - 1.08% Warrants As of September 30, 2024 and June 30, 2024, the Company had 118,968,828 warrants outstanding. The warrants have a term of two to five years and an exercise price range from $0.021 and $0.1187. The Company evaluated the warrants under ASC 815, Derivatives and Hedging Number of Warrants Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2024 118,968,828 $ 0.09 2.50 $ - Granted - Exercised - Canceled Outstanding at September 30, 2024 118,968,828 $ 0.09 2.30 $ - Vested at September 30, 2024 118,968,828 $ 0.09 2.30 $ - Exercisable at September 30, 2024 118,968,828 $ 0.09 2.30 $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2024
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS On October 1, 2024, the Company issued 2,200,000 common shares that were converted from 2,200 Series A preferred shares. On October 1, 2024, the Company issued 8,800,000 common shares that were converted from convertible notes with a principal amount of $80,000 and accrued interest of $8,000. On October 21, 2024, the Company issued 5,500,000 common shares that were converted from convertible notes with a principal amount of $50,000 and accrued interest of $5,000. On October 22, 2024, the Company issued 1,000,000 common shares that were converted from 1,000 Series A preferred shares. On October 25, 2024, the Company issued 2,200,000 common shares that were converted from convertible notes with a principal amount of $20,000 and accrued interest of $2,000. On November 4, 2024, 1,000,000 common shares were cancelled reversing the issuance on October 22, 2024.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The unaudited condensed consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC and BlueGreen Composites, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) for interim information and in accordance with the instructions to Form 10Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. All significant intercompany balances and transactions have been eliminated. The unaudited condensed consolidated financial statements, which include the accounts of the Company and its subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with U.S. GAAP and presented in US dollars. The fiscal year end is June 30.
Going Concern	These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred net losses since inception and has an accumulated deficit of $27,073,761 as of September 30, 2024. During the three months ended September 30, 2024, the Company’s net loss was $372,222 and at September 30, 2024, the Company had a working capital deficit of $8,532,513. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on its historical rate of expenditures, the Company expects to expend its available cash in approximately two months from November 14, 2024. Management’s plans include raising capital through the issuance of common stock and debt to fund operations and, eventually, the generation of revenue through its business. The Company does not expect to generate any significant revenue in the foreseeable future. The Company is in immediate need of further working capital and is seeking options, with respect to financing, in the form of debt, equity or a combination thereof. Failure to raise adequate capital and generate adequate revenues could result in the Company having to curtail or cease operations. The Company’s ability to raise additional capital through the future issuances of the common stock is unknown. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable it to develop to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern; however, the accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Principles of Consolidation	The unaudited condensed consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC and BlueGreen Composites, LLC. The Company owns a 64% controlling interest in AAT; and a 100% interest in BlueGreen Composites, LLC. All intercompany balances and transactions have been eliminated.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of warrants associated with convertible debt. Actual results could differ from these estimates.
Fair Value Measurements and Fair Value of Financial Instruments	The Company adopted Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3: Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements. ASC subtopic 825-10, Financial Instruments The Company follows ASC subtopic 820-10, Fair Value Measurements and Disclosures
Cash and Cash Equivalents	For the purposes of the unaudited condensed consolidated statements of cash flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents.
Impairment of Long-Lived Assets	In accordance with ASC 360-10, Impairment and Disposal of Long-Lived Asset
Convertible Debentures	The Company adheres to the guidance in Accounting Standards Updated (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity on July 1, 2022
Stock-based Compensation	The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period. During the three months ended September 30, 2024 and 2023, the Company recognized $217,512 and $0, respectively.
Leases	The Company accounts for leases under ASU 2016-02. At the inception of a contract the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease right of use (“ROU”) assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is presented in operating expenses on the unaudited condensed consolidated statements of operations as rent expense. Finance leases are recorded as a finance lease liability and property and equipment asset, based on the present value of lease payments. The asset is depreciated, and the liability is amortized with interest expense incurred over the life of the lease. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the guidance to short term leases (leases with a lease term of twelve months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term.
Investments	The Company follows ASC 325-20, Cost Method Investments
Research and Development Expenses	Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $26,561 and $26,982 for the three months ended September 30, 2024 and 2023, respectively.
Advertising and Marketing Expenses	The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $2,035 and $6,356 for the three months ended September 30, 2024 and 2023, respectively, as general and administrative expenses.
Income Taxes	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s consolidated federal tax return and any state tax returns are not currently under examination. The Company follows ASC subtopic 740-10, Income Taxes
Basic Income (Loss) Per Share	Under the provisions of ASC 260, “ Earnings per Share Three months ended September 30, 2024 2023 Warrants 118,968,828 104,802,161 Stock options 21,250,000 21,250,000 Convertible notes payable 861,438,676 103,383,909 Preferred stock 699,416,000 752,395,000 Total 1,701,073,504 981,831,070
Recent Accounting Pronouncements	All other recent accounting pronouncements issued by the Financial Accounting Standards Board, did not or are not believed by management to have a material impact on the Company’s present or future unaudited condensed consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Sep. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of potentially dilutive common securities	Three months ended September 30, 2024 2023 Warrants 118,968,828 104,802,161 Stock options 21,250,000 21,250,000 Convertible notes payable 861,438,676 103,383,909 Preferred stock 699,416,000 752,395,000 Total 1,701,073,504 981,831,070

JOINT VENTURE (Tables)

JOINT VENTURE (Tables)	3 Months Ended
	Sep. 30, 2024
JOINT VENTURE
Schedule consolidated VIE's assets and liabilities associated with the VIE subsidiary	September 30, 2024 June 30, 2024 Assets Cash $ - $ - Total Assets $ - $ - Liabilities Due from Xeriant Inc. $ 4,475,155 $ 4,475,155 Total Liabilities $ 4,475,155 $ 4,475,155

OPERATING LEASE RIGHTOFUSE ASSE

OPERATING LEASE RIGHTOFUSE ASSET AND OPERATING LEASE LIABILITY (Tables)	3 Months Ended
	Sep. 30, 2024
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Schedule of Rent periods	November 1, 2019 to October 31, 2020 $ 4,367 November 1, 2020 to October 31, 2021 $ 4,498 November 1, 2021 to October 31, 2022 $ 4,633 November 1, 2022 to October 31, 2023 $ 4,772 November 1, 2023 to October 31, 2024 $ 4,915 November 1, 2024 to January 31, 2025 $ 5,063
Summary of Right-of-use assets, net	September 30, 2024 June 30, 2024 Office lease $ 220,448 $ 220,448 Less accumulated amortization (201,761 ) (188,195 ) Right of use assets, net $ 18,687 $ 32,253
Summary of Operating lease liability	September 30, 2024 June 30, 2024 Office lease $ 21,144 $ 36,197 Less: current portion (21,144 ) (36,197 ) Long term portion $ - $ -
Summary of maturity of lease liability	Year ended June 30, 2025 21,410 Total future minimum lease payments 21,410 Less: Present value discount (266 ) Lease liability $ 21,144

CONVERTIBLE NOTES PAYABLE, IN_2

CONVERTIBLE NOTES PAYABLE, IN DEFAULT (Tables)	3 Months Ended
	Sep. 30, 2024
CONVERTIBLE NOTES PAYABLE, IN DEFAULT
Schedule of convertible notes payable	September 30, June 30, Convertible Notes Payable 2023 2023 Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC $ 5,850,000 $ 5,850,000 Total face value $ 5,850,000 $ 5,850,000

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	3 Months Ended
	Sep. 30, 2024
CONVERTIBLE NOTES PAYABLE
Convertible notes payable, net of discount	September 30, June 30, Convertible Notes Payable 2024 2024 Convertible notes payable (10% interest) $ 1,905,000 $ 2,180,000 Less unamortized discount (30,669 ) (47,471 ) Total face value $ 1,874,331 $ 2,132,529
Redemption feature component of the warrants	Quoted market price on valuation date $0.016 - $0.022 Effective contractual conversion rates $0.01 Contractual term to maturity 3 years Market volatility: Volatility 137.43% - 137.86% Risk-adjusted interest rate 4.33% - 4.39%

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Sep. 30, 2024
EQUITY
Schedule of stock options activity	Number of Options Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2024 21,250,000 $ 0.12 1.11 Granted - Exercised - - Canceled - - Outstanding at September 30, 2024 21,250,000 $ 0.12 0.76 $ - Exercisable at September 30, 2024 21,250,000 $ 0.12 0.30 $ -
Schedule of Black-Scholes process	Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility: Range of equivalent volatility 181.21% - 275.73% Range of interest rates 0.20% - 1.08%
Schedule of stock warrants activity	Number of Warrants Number of Warrants Weighted- Average Exercise Price Weighted- Average Contractual Term (in years) Aggregate Intrinsic Value Outstanding at June 30, 2024 118,968,828 $ 0.09 2.50 $ - Granted - Exercised - Canceled Outstanding at September 30, 2024 118,968,828 $ 0.09 2.30 $ - Vested at September 30, 2024 118,968,828 $ 0.09 2.30 $ - Exercisable at September 30, 2024 118,968,828 $ 0.09 2.30 $ -

ORGANIZATION AND NATURE OF BU_2

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 25, 2023	Sep. 30, 2024
Development expense in joint venture		$ 5,500,000
Pre-orders and reservations amount		$ 7,000,000,000
XTI JV [Member]
Description of merger agreements	On July 25, 2023, Inpixon filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding, which was a compensation triggering event. Inpixon subsequently filed an S-4/A registration statement on October 6, 2023

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Warrants	118,968,828	104,802,161
Stock options	21,250,000	21,250,000
Convertible notes payable	861,438,676	103,383,909
Preferred stock	699,416,000	752,395,000
Total	1,701,073,504	981,831,070

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Stock-based compensation expense	$ 217,512	$ 0
Research and development expenses	26,561	26,982
Accumulated deficit	(27,073,761)		$ (26,708,915)
Working capital deficit	(8,532,513)
Net Loss	$ (372,222)	(342,012)
Ownership percentage	64%
Advertising expenses	$ 2,035	$ 6,356
Ebenberg LLC Joint Venture [Member]
Ownership percentage	100%

JOINT VENTURE (Details)

JOINT VENTURE (Details) - VIE Unauited Condensed Consolidated Balance Sheet [Member] - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Cash	$ 0	$ 0
Total Assets	0	0
Due from Xeriant Inc.	4,475,155	4,475,155
Total Liabilities	$ 4,475,155	$ 4,475,155

JOINT VENTURE (Details Narrativ

JOINT VENTURE (Details Narrative) - XTI JV [Member] - USD ($)	1 Months Ended
	Jul. 25, 2023	May 31, 2021	Sep. 30, 2024
Ownership owned percentage		50%
Initial Deposit		$ 5,500,000
Description of merger agreement	filed an 8-K, announcing their intention to merge with XTI having executed an Agreement of Plan and Merger with XTI. The filing also showed that XTI had engaged in a transaction with Inpixon on March 10, 2023, receiving $300,000 in funding, which was a compensation triggering event. Inpixon subsequently filed an S-4/A registration statement on October 6, 2023
Investment in joint venture			$ 10,000,000

CONCENTRATION OF CREDIT RISKS (

CONCENTRATION OF CREDIT RISKS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024
CONCENTRATION OF CREDIT RISKS
Cash in excess of FDIC insurance	$ 0	$ 0

OPERATING LEASE RIGHT OF USE _2

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details)	3 Months Ended
	Sep. 30, 2024 USD ($)
November 1, 2022 to October 31, 2023 [Member]
Base rent	$ 4,772
November 1 2020 to October 31 2021 [Member]
Base rent	4,498
November 1, 2021 to October 31, 2022 [Member]
Base rent	4,633
November 1 2023 to October 31 2024 [Member]
Base rent	4,915
November 1, 2024 to January 31, 2025 [Member]
Base rent	5,063
November 1, 2019 to October 31, 2020 [Member]
Base rent	$ 4,367

OPERATING LEASE RIGHT OF USE _3

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 1) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Office lease	$ 220,448	$ 220,448
Less accumulated amortization	(201,761)	(188,195)
Right-of-use assets net	$ 18,687	$ 32,253

OPERATING LEASE RIGHT OF USE _4

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 2) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY
Operating lease liability, Office lease	$ 21,144	$ 36,197
Operating lease liability, Less current portion	(21,144)	(36,197)
Operating lease liability, Long term portion	$ 0	$ 0

OPERATING LEASE RIGHT OF USE _5

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details 3)	Sep. 30, 2024 USD ($)
Maturity of the lease liability is as follows
Year ended June 30, 2025	$ 21,410
Total future minimum lease payments	21,410
Less: Present value discount	(266)
Lease liability	$ 21,144

OPERATING LEASE RIGHT OF USE _6

OPERATING LEASE RIGHT OF USE ASSET AND OPERATING LEASE LIABILITY (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Interest Rate	10%
Lease Agreement [Member]
Capital Leases Description	The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University
General and administrative expenses [Member]
Rent expense	$ 13,257	$ 13,285

CONVERTIBLE NOTES PAYABLE IN DE

CONVERTIBLE NOTES PAYABLE IN DEFAULT (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Total face value	$ 5,850,000	$ 5,850,000
Convertible notes payable issued October 27, 2021
Total face value	$ 5,850,000	$ 5,850,000

CONVERTIBLE NOTES PAYABLE IN _2

CONVERTIBLE NOTES PAYABLE IN DEFAULT (Details Narrative) - USD ($)				1 Months Ended				3 Months Ended		12 Months Ended
	Apr. 05, 2024	Oct. 06, 2023	Jan. 15, 2023	Feb. 15, 2023	Dec. 27, 2022	Jul. 26, 2022	Oct. 27, 2021	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Default interest										$ 1,070,729
Carrying value of convertible notes payable, net of discount									$ 5,850,000		$ 5,850,000
Accounts payable and accrued liabilities								$ 50,000
Professional fees								63,806	$ 90,314
Interest amount convertible to common stock	$ 227,067	$ 200,115
Converted in interest into shares of common stock	22,706,700	20,011,500
Accrued interest								$ 643,546
First Amendment [Member]
Loss on an extinguishment debt											(3,570,366)
Second Amendment [Member]
Loss on an extinguishment debt											$ (689,621)
Secured Debt [Memebr] | Senior Secured Note [Member] | Auctus Fund, LLC [Member]
Original issue discount							$ 907,500
Debt instrument converted principal amount							6,050,000
Purchase price							$ 5,142,500
Conversion price							$ 0.1187
Aggregate warrant issued of common stock							50,968,828
Exercise price							$ 0.1187
Professional fees							$ 433,550
Closing costs							$ 308,550
Offering price							75%
Secured Debt [Memebr] | Promissory Note [Member] | Auctus Fund, LLC [Member] | October 27, 2021 [Member]
Exercise price					$ 0.09	$ 0.09
Maturity date					Mar. 15, 2023	Nov. 01, 2022
Term year					5 years	5 years
New warrant to purchase shares of Common Stock					250,000,000	25,000,000
Prepayment of the Note			$ 50,000	$ 50,000		$ 100,000
Conversion to issue shares of common stock					20,011,500

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
CONVERTIBLE NOTES PAYABLE
Convertible notes payable	$ 1,905,000	$ 2,180,000
Less unamortized discount	(30,669)	(47,471)
Total face value	$ 1,874,331	$ 2,132,529

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details 1)	3 Months Ended
	Sep. 30, 2024 $ / shares
Effective contractual conversion rates	$ 0.01
Contractual term to maturity	3 years
Minimum [Member] | BSM [Member]
Risk-adjusted interest rate	137.43%
Volatility	4.33%
Quoted market price on valuation date	$ 0.016
Maximum [Member] | BSM [Member]
Risk-adjusted interest rate	4.39%
Volatility	137.86%
Quoted market price on valuation date	$ 0.022

CONVERTIBLE NOTES PAYABLE (De_3

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Common stock share issued for conversion	26,950,000
Interest expenses			$ 1,070,729
Accrued interest	$ 269,501
Black-Scholes Merton (BSM) [Member]
Warrants value	$ 66,660
Between July 17, 2023 and June 26, 2024 [Member]
Convertible at fixed price	$ 0.01
Interest expenses	$ 61,617	$ 20,674
Exercise price	$ 0.01
Convertible bridge loans, aggregate face value	$ 2,030,000
Principal amount	$ 150,000
Warrants issued	15,000,000
Interest rate	10%
Convertible Bridge Loans [Member]
Common stock share issued for conversion	26,950,000
Debt instrument at fair value	$ 249,702
Convertible notes payable, aggregate face value	270,000
Principal amount	245,000
Accrued interest	$ 24,501

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Ancient Investments, LLC
Consulting fees	$ 55,000	$ 57,500
Accrued liability	2,500	5,000
Edward DeFeudis
Consulting fees	30,000	21,000
Accrued liability	10,000	10,000
AMP Web Services
Consulting fees	23,000	14,000
Accrued liability	0	0
Keystone Business Development Partners [Member]
Consulting fees	15,000	5,000
Accrued liability	$ 5,000	$ 5,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended						3 Months Ended
	Mar. 01, 2022	Mar. 20, 2022	Jan. 20, 2022	Aug. 20, 2021	Aug. 09, 2021	Jul. 28, 2021	Jul. 06, 2021	Sep. 30, 2024	Sep. 30, 2023
Stock issued during priod shares new issues								1,701,073,504	981,831,070
Advisory Board [Member]
Common shares cash amount paid per meeting	$ 2,500	$ 2,500	$ 2,500	$ 2,500	$ 2,500	$ 2,500	$ 2,500
Stock issued during priod shares new issues	150,000	150,000	150,000	100,000	50,000	250,000
Additional bonus paid common shares issued for services		$ 25,000		$ 25,000		$ 25,000	$ 25,000
Warrant options to common shares				4,000,000		5,000,000	5,000,000
Common stock shares issuedsold price per share				$ 0.12		$ 0.12	$ 0.12
Common share opened a strategic bonus	25,000		25,000		25,000	5,000,000	250,000
Advisory Board [Member] | July 1 2021 [Member]
Common shares cash amount paid per meeting								$ 2,500
Stock issued during priod shares new issues								100,000
Additional bonus paid common shares issued for services								$ 25,000
Warrant options to common shares								1,000,000
Common stock shares issuedsold price per share								$ 0.12
Average market price								25%
Option to purchase shares								5,000,000
Trading days								10 years
Finders fee								1%

EQUITY (Details)

EQUITY (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Number of Shares
Outstanding, Beginning	21,250,000	21,250,000
Outstanding at Ending	21,250,000	21,250,000
Exercisable at Ending	21,250,000	21,250,000
Weighted Average Exercise Price
Outstanding, Beginning	$ 0.12	$ 0.12
Exercised	0	0
Canceled	0	0
Outstanding at Ending	0.12	$ 0.12
Exercisable at Ending	$ 0.12
Weighted Average Remaining Contractual Term
Outstanding at Beginning	1 year 1 month 9 days	1 year 9 months 18 days
Outstanding at Ending	9 months 3 days	11 months 19 days
Exercisable at Ending	3 months 18 days	1 month 17 days
Aggregate Intrinsic Value
Outstanding at Ending	$ 0
Exercisable at Ending	$ 0

EQUITY (Details 1)

EQUITY (Details 1) - Stock Option [Member]	3 Months Ended
	Sep. 30, 2024 $ / shares
Exercise price	$ 0.12
Maximum [Member]
Quoted market price on valuation date	$ 0.23
Range of expected term	2 years 5 months 26 days
Range of interest rate	1.08%
Range of equivalent volatility	275.73%
Minimum [Member]
Quoted market price on valuation date	$ 0.169
Range of expected term	1 year 6 months 18 days
Range of interest rate	0.20%
Range of equivalent volatility	181.21%

EQUITY (Details 2)

EQUITY (Details 2)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Weighted average contractual term [Member]
Weighted average contractual term, beginning	2 years 6 months
Weighted average contractual term, Vested	2 years 3 months 18 days
Weighted average contractual term, ending	2 years 3 months 18 days
Weighted average contractual term, Exercisable	2 years 3 months 18 days
Weighted Average Exercise Price [Member]
Weighted average exercise price, beginning | $ / shares	$ 0.09
Weighted average exercise price, Vested and expected to vest | $ / shares	0.09
Weighted average exercise price, Ending | $ / shares	0.09
Weighted average exercise price, Exercisable | $ / shares	$ 0.09
Warrants [Member]
Outstanding, Beginning	118,968,828
Granted	0
Canceled	0
vested	118,968,828
Outstanding, Ending balance	118,968,828
Exercisable	118,968,828

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Jun. 30, 2022	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023
Common stock, shares authorized	5,000,000,000		5,000,000,000
Common stock, shares par value	$ 0.00001		$ 0.00001
Common stock, shares, issued	570,184,486		524,853,304
Common stock, shares outstanding	570,184,486		524,853,304
Conversion of Stock in Principal amount	$ 245,000
Accrued interest	$ 269,501
Common stock share issued for conversion	26,950,000
Number of shares Options outstanding	21,250,000		21,250,000	21,250,000	21,250,000
Number of shares Options exercisable	21,250,000			21,250,000
Series B Preferred Shares [Member]
Conversion of Series A Preferred to Common Stock, shares	5,000
Preferred stock, shares authorized	100,000,000		100,000,000
Preferred stock, shares par value	$ 0.00001		$ 0.00001
Preferred stock, shares designated	1,000,000		1,000,000
Preferred stock, shares issued	1,000,000		1,000,000
Preferred stock, shares outstanding	1,000,000		1,000,000
Series A Preferred Stock shares [Member]
Share issued for exchange conversion, shares	3,500,000
Conversion of Series A Preferred to Common Stock, shares	51,500
Preferred stock, shares authorized	100,000,000		100,000,000
Preferred stock, shares par value	$ 0.00001		$ 0.00001
Preferred stock, shares designated			3,500,000
Voting description	1,000 votes to every one share of common stock
Conversion description	1:1,000
Preferred stock, shares issued	699,416		705,895
Preferred stock, shares outstanding	699,416		705,895
Warrants [Member]
Number of warrants Outstanding	104,802,161		118,968,828
Warrants [Member] | Minimum [Member]
Wighted average remaining useful life of warrants	2 years
Exercise price	$ 0.01
Warrants [Member] | Maximum [Member]
Wighted average remaining useful life of warrants	5 years
Exercise price	$ 0.1187
Stock Option [Member]
Number of shares Options outstanding		21,250,000	21,250,000
Number of shares Options exercisable			21,250,000
Stock options weighted average remaining term	3 months 18 days
Fair value of stock option		$ 3,964,207
Exercise price		$ 0.12

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			1 Months Ended
	Nov. 04, 2024	Oct. 02, 2024	Oct. 25, 2024	Oct. 22, 2024	Oct. 21, 2024	Oct. 01, 2024	Sep. 30, 2024
Accrued interest							$ 643,546
Series A Preferred Shares [Member]
Issued shares of common stock for compensation, shares		2,200,000		1,000,000
Convertible notes total face value				$ 1,000		$ 2,200
Subsequent Event [Member]
Issued shares of common stock for compensation, shares		8,800,000	2,200,000		5,500,000
Convertible notes total face value			$ 20,000		$ 50,000	80,000
Number of shares cancelled	1,000,000
Accrued interest			$ 2,000		$ 5,000	$ 8,000